DOI: 10.1055/s-00034915

Onkologische Welt

LinksSchließen

Referenz

Maluf FC. et al
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus APA plus AAP in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)..
ASCO 2020 Abstract 5505

Bibliographische Angaben herunterladen

Aufrufen in: